Marjan Sepassi

Company: Clene Nanomedicine

Job title: Vice President - Medical Affairs

Seminars:

Reinventing the Surrogate Landscape: Innovating Regulatory Acceptable Endpoints Most Meaningful to People Living with ALS 2:05 pm

The recent accelerated approval brings new waves of promise for transformative ALS drugs to be approved based on surrogate markers that correlate with ALSFRS-R. With increasing demand to define more acceptable endpoints for ALS, collaborate with industry sponsors and regulatory experts to: Evaluate the potential of novel surrogate biomarkers that extend beyond ALSFRS-R to monitor…Read more

day: Pre-Conference Day